Interleukin-6-deficient Mice Develop Hepatic Inflammation and Systemic Insulin Resistance

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Aug 11

PMID 20697689

Citations 154

Authors

V B Matthews

T L Allen

S Risis

M H S Chan

D C Henstridge

N Watson

L A Zaffino

J R Babb

J Boon

P J Meikle

J B Jowett

M J Watt

J-O Jansson

C R Bruce

M A Febbraio

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: The role of IL-6 in the development of obesity and hepatic insulin resistance is unclear and still the subject of controversy. We aimed to determine whether global deletion of Il6 in mice (Il6 (-/-)) results in standard chow-induced and high-fat diet (HFD)-induced obesity, hepatosteatosis, inflammation and insulin resistance.

Methods: Male, 8-week-old Il6 (-/-) and littermate control mice were fed a standard chow or HFD for 12 weeks and phenotyped accordingly.

Results: Il6 (-/-) mice displayed obesity, hepatosteatosis, liver inflammation and insulin resistance when compared with control mice on a standard chow diet. When fed a HFD, the Il6 (-/-) and control mice had marked, equivalent gains in body weight, fat mass and ectopic lipid deposition in the liver relative to chow-fed animals. Despite this normalisation, the greater liver inflammation, damage and insulin resistance observed in chow-fed Il6 (-/-) mice relative to control persisted when both were fed the HFD. Microarray analysis from livers of mice fed a HFD revealed that genes associated with oxidative phosphorylation, the electron transport chain and tricarboxylic acid cycle were uniformly decreased in Il6 (-/-) relative to control mice. This coincided with reduced maximal activity of the mitochondrial enzyme β-hydroxyacyl-CoA-dehydrogenase and decreased levels of mitochondrial respiratory chain proteins.

Conclusions/interpretation: Our data suggest that IL-6 deficiency exacerbates HFD-induced hepatic insulin resistance and inflammation, a process that appears to be related to defects in mitochondrial metabolism.

Citing Articles

Eye on the horizon: The metabolic landscape of the RPE in aging and disease.

Hansman D, Du J, Casson R, Peet D Prog Retin Eye Res. 2024; 104:101306.

PMID: 39433211 PMC: 11833275. DOI: 10.1016/j.preteyeres.2024.101306.

Altered Cytokine Secretory Fingerprint of the Adipocytes Derived from Stem Cells of Morbidly Obese Patients-A Preliminary Study.

Lukaszuk B, Supruniuk E, Chabowski A, Miklosz A Cells. 2024; 13(19.

PMID: 39404367 PMC: 11475718. DOI: 10.3390/cells13191603.

Wound Closure Promotion by Leucine-Based Pseudo-Proteins: An In Vitro Study.

Ksovreli M, Kachlishvili T, Skhvitaridze M, Nadaraia L, Goliadze R, Kamashidze L Int J Mol Sci. 2024; 25(17).

PMID: 39273588 PMC: 11395615. DOI: 10.3390/ijms25179641.

NAMPT, IL-6, and vaspin gene expressions and serum protein levels in type 2 diabetes mellitus and related complication.

Celik S, Parilti D, Acik L, Yalcin M, Yetkin I, Yunusov E Turk J Biol. 2024; 48(2):133-141.

PMID: 39051061 PMC: 11265895. DOI: 10.55730/1300-0152.2688.

Myeloid-derived grancalcin instigates obesity-induced insulin resistance and metabolic inflammation in male mice.

Su T, He Y, Huang Y, Ye M, Guo Q, Xiao Y Nat Commun. 2024; 15(1):97.

PMID: 38167327 PMC: 10762069. DOI: 10.1038/s41467-023-43787-x.

References

Sadagurski M, Norquay L, Farhang J, DAquino K, Copps K, White M . Human IL6 enhances leptin action in mice. Diabetologia. 2009; 53(3):525-35. PMC: 2815798. DOI: 10.1007/s00125-009-1580-8. View

Solinas G, Naugler W, Galimi F, Lee M, Karin M . Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006; 103(44):16454-9. PMC: 1637603. DOI: 10.1073/pnas.0607626103. View

Garcia M, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O . Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes. 2006; 55(5):1205-13. DOI: 10.2337/db05-1304. View

Klover P, Clementi A, Mooney R . Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005; 146(8):3417-27. DOI: 10.1210/en.2004-1468. View

Patti M, Butte A, Crunkhorn S, Cusi K, Berria R, Kashyap S . Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003; 100(14):8466-71. PMC: 166252. DOI: 10.1073/pnas.1032913100. View

Starkie R, Ostrowski S, Jauffred S, Febbraio M, Pedersen B . Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003; 17(8):884-6. DOI: 10.1096/fj.02-0670fje. View

Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T . Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994; 368(6469):339-42. DOI: 10.1038/368339a0. View

Pedersen B, Febbraio M . Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008; 88(4):1379-406. DOI: 10.1152/physrev.90100.2007. View

Petersen E, Carey A, Sacchetti M, Steinberg G, Macaulay S, Febbraio M . Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab. 2004; 288(1):E155-62. DOI: 10.1152/ajpendo.00257.2004. View

10.

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z, Karin M . Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001; 293(5535):1673-7. DOI: 10.1126/science.1061620. View

11.

Perez-Carreras M, del Hoyo P, Martin M, Rubio J, Martin A, Castellano G . Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003; 38(4):999-1007. DOI: 10.1053/jhep.2003.50398. View

12.

Petersen K, Dufour S, Befroy D, Garcia R, Shulman G . Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004; 350(7):664-71. PMC: 2995502. DOI: 10.1056/NEJMoa031314. View

13.

Hirosumi J, Tuncman G, Chang L, Gorgun C, Uysal K, Maeda K . A central role for JNK in obesity and insulin resistance. Nature. 2002; 420(6913):333-6. DOI: 10.1038/nature01137. View

14.

Rotter Sopasakis V, Larsson B, Johansson A, Holmang A, Smith U . Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia. 2004; 47(11):1879-87. DOI: 10.1007/s00125-004-1544-y. View

15.

Lazar M . How obesity causes diabetes: not a tall tale. Science. 2005; 307(5708):373-5. DOI: 10.1126/science.1104342. View

16.

Feve B, Bastard J . The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5(6):305-11. DOI: 10.1038/nrendo.2009.62. View

17.

Fosgerau K, Galle P, Hansen T, Albrechtsen A, Rieper C, Pedersen B . Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J Endocrinol. 2009; 204(3):265-73. DOI: 10.1677/JOE-09-0413. View

18.

Holmes A, Mesa J, Neill B, Chung J, Carey A, Steinberg G . Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J Endocrinol. 2008; 198(2):367-74. DOI: 10.1677/JOE-08-0113. View

19.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

20.

Klover P, Zimmers T, Koniaris L, Mooney R . Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003; 52(11):2784-9. DOI: 10.2337/diabetes.52.11.2784. View